Skip to content

A prospective single arm multicenter study of immune tolerance induced by modified post cyclophosphamide combined with mycophenolate mofetil after allogeneic peripheral blood stem cell transplantation

A prospective single arm multicenter study of immune tolerance induced by modified post cyclophosphamide combined with mycophenolate mofetil after allogeneic peripheral blood stem cell transplantation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064513
Enrollment
Unknown
Registered
2022-10-10
Start date
2022-10-08
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group A:try regimen

Sponsors

Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 2 to 40 years old (including 2 and 40 years old); 2. Have indications for allogeneic hematopoietic stem cell transplantation; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Symptomatic coronary heart disease; 2. The physical fitness score is less than 70 points; 3. Cardiac ejection fraction is less than 50%; 4. Creatinine clearance rate is less than 50 ml/min; 5. HCT-specific prognostic index (HCT-CT) greater than 3 (including 3 points); 6. Uncontrolled viral, bacterial and fungal infections (the disease is still progressing during antifungal treatment); 7. HIV seropositive; 8. History of other systemic malignancies; 9. Pregnant and lactating women; 10. Men and women who do not agree to contraception during the trial period; 11. The researcher considers it inappropriate to enroll.

Design outcomes

Primary

MeasureTime frame
Engraftment incidence;Incidence and extent of graft-versus-host disease;

Countries

China

Contacts

Public ContactBin Fu

Xiangya Hospital of Central South University

xyfubin@126.com+86 13755006662

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026